Still's disease, also known as Adult-onset Still's Disease (AOSD), is a rare inflammatory disease characterized by joint pain, rash, and fever. This devastating condition can lead to long-term chronic arthritis and permanent injuries. Still's disease is associated with a rash that does not itch and a high fever. This disorder can destroy the affected joints, especially the wrists. Treatment for Still's disease includes anti-inflammatory medications. Still's disease is a rare rheumatic disease. This disease is characterized by biological and clinical symptoms such as high fever, joint swelling, myalgia, sore throat, increase in white blood cells (leukocytes, especially neutrophils), and biological hepatitis. Treatment for Still's disease can be divided into two categories, namely symptomatic treatments and effective treatments. Symptomatic treatment can be started immediately even if the diagnosis is not confirmed, while effective treatment methods are designed to treat the disease more effectively to eliminate the symptoms of the disease.

Market Dynamics

Increasing practices of treatments, mergers, and acquisitions by key market players are expected to drive the global Still’s disease treatment market growth. For instance, on April 13, 2023, Metropolis Healthcare noted that treatment of Still's disease with nonsteroidal anti-inflammatory drugs (NSAIDs), these medications reduce inflammatory pain and the signs and symptoms of Still’s disease. Corticosteroids reduce inflammation by reducing the activity of the immune system. Disease-modifying Antirheumatic Drugs (DMARDs) can help slow down the progress of Still’s disease and reduce the frequency of flares. Physical therapy, exercise, rest, and a healthy diet can help manage the condition and keep symptoms to a minimum.

Key features of the study:

• This report provides an in-depth analysis of the global Still’s disease treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Still’s disease treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as a part of this study include AB2 Bio Ltd , F.offmann-La Roche Ltd, Novartis AG, Swedish Orphan Biovitrum AB, Jubilant Life Sciences Ltd, Vintage Labs, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd, Mylan N.V, Horizon Therapeutics plc, Sun Pharmaceutical Industries Ltd, Zydus Cadila, Amneal Pharmaceuticals LLC, Dr Reddy's Laboratories Ltd, and Fresenius Kabi AG
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Still’s disease treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Still’s disease treatment market

Detailed Segmentation:

• Global Still’s Disease Treatment Market, By Treatment :
  • Pain Management
  • Corticosteroids
  • Tocilizumab
  • Canakinumab
  • Others
• Global Still’s Disease Treatment Market, By Route of Administration :
  • Injectables
  • Oral
• Global Still’s Disease Treatment Market, By Distribution Channels :
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
• Global Still’s Disease Treatment Market, By Region:
  • North America
    
    • U.S.
    • Canada
  • Latin America
    
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • AB2 Bio Ltd.
  • F.Hoffmann-La Roche Ltd
  • Novartis AG
  • Swedish Orphan Biovitrum AB
  • Jubilant Life Sciences Ltd
  • Vintage Labs
  • Hikma Pharmaceuticals PLC
  • Teva Pharmaceutical Industries Ltd
  • Mylan N.V
  • Horizon Therapeutics plc
  • Sun Pharmaceutical Industries Ltd
  • Zydus Cadila
  • Amneal Pharmaceuticals LLC
  • Dr Reddy's Laboratories Ltd
  • Fresenius Kabi AG

 “*” marked represents similar segmentation in other categories in the respective section